AMGN: Rounding Bottom detected on 3 Nov 2026

AMGEN has formed a rounding bottom pattern with near-perfect structure (15.0/15). The stock is trading at $465.45, positioned 2.14% below its 52-week high and 66% above its 52-week low, indicating recovery from lows of $316.25 (key support). Resistance sits at $368.39. The pattern shows solid breakout quality (10.0/13) and moderate volume confirmation (11.08/12) at 1.22x average daily volume. RSI at 70.96 signals overbought conditions. The overall score of 75.08 reflects a high-quality setup with 72% win probability, though recent performance (15.5% monthly gain, 20% quarterly gain) has already generated significant momentum into this pattern.

AMGEN reported strong Q2 2026 results with 10% revenue growth and raised its 2026 outlook, with coverage centered on a stronger drug mix and clinical progress for Tezspire. The company is scheduled to report third-quarter 2026 financial results on November 3, 2026, after market close—today. Recent catalysts include positive Phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease announced 28 days ago and fresh trial data for IMDELLTRA in extensive-stage small cell lung cancer and Tezspire in eosinophilic esophagitis. However, the company faces regulatory pressure on Tavneos and questions about offsetting older-product declines. The healthcare sector remains in bullish regime (0.81 score), supporting biotech strength, though legacy moats like Prolia and Enbrel are eroding at 30%+ year-over-year.

A successful rounding bottom breakout above $368.39 resistance would target $488.91 conservatively, representing a 5% move from current price. The breakout requires sustained volume confirmation above 20-day average (currently 1.22x ratio, adequate but not exceptional). Historical rounding bottoms with this pattern quality score show 72% win probability. The setup invalidates below key support at $316.25, which would represent a 32% loss from current levels. Volume should expand on any break above resistance to confirm institutional accumulation. The measured move reflects typical rounding bottom proportions relative to pattern depth.

AMGEN reports earnings today after market close, creating binary risk that could negate the technical setup with unexpected guidance or pipeline updates. RSI at 70.96 indicates overbought conditions, suggesting potential near-term pullback before breakout confirmation. Valuation concern: Simply Wall St pegs fair value at $359.98 versus last close of $466.01, suggesting 29% overvaluation that contrasts with recent price strength. Regulatory headwinds persist—FDA cited Amgen's video ads for Vectibix as 'false or misleading' on October 27. Beta of -0.07 is unusual (inverse market correlation), which could create execution risk if biotech sector reverses. Legacy product erosion at 30%+ YoY clip poses structural headwind despite pipeline strength.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.